Aoki Y, Yoshihara F, Kondoh M, Nakamura Y, Nakayama N, Arisawa M
Nippon Roche Research Center, Kamakura, Japan.
Antimicrob Agents Chemother. 1993 Dec;37(12):2662-7. doi: 10.1128/AAC.37.12.2662.
Ro 09-1470 is a new antifungal agent that belongs to a series of compounds characterized by a tetrahydropyran skeleton with glycine and alkenyl side chains and that inhibits P-450 lanosterol C-14 demethylase (P-450(14DM)) of fungi (Y. Aoki, T. Yamazaki, M. Kondoh, Y. Sudoh, N. Nakayama, Y. Sekine, H. Shimada, and M. Arisawa, J. Antibiot. 45:160-170, 1992; S. Matsukuma, T. Ohtsuka, H. Kotaki, H. Sawairi, T. Sano, K. Watanabe, N. Nakayama, Y. Itezono, M. Fujiu, N. Shimma, K. Yokose, and T. Okuda, J. Antibiot. 45:151-159, 1992). We have studied the compound's mode of interaction with fungal P-450(14DM) and its selectivity for the fungal versus mammalian P-450 enzymes. Ro 09-1470 bound to the Saccharomyces cerevisiae P-450(14DM) by coordinating to the heme with one-to-one stoichiometry. Unlike the azole compounds, it interacted with both ferric and ferrous heme. It was active also against the P-450(14DM) of Candida albicans. Ro 09-1470 preferentially inhibited the yeast P-450(14DM), showing a 50% inhibitory concentration (IC50) of 0.47 to approximately 1.1 microM, which is much lower than the IC50s for rat hepatic P-450s catalyzing cholesterol biosynthesis (IC50 = 341 microM), p-nitroanisol O-demethylation (> 1,000 microM), aniline hydroxylation (> 1,000 microM), and aminopyrine N-demethylation (920 microM). The degree of selectivity for yeast P-450 was higher than that of ketoconazole.
Ro 09 - 1470是一种新型抗真菌剂,属于一系列具有四氢吡喃骨架、带有甘氨酸和烯基侧链的化合物,它能抑制真菌的P - 450羊毛甾醇C - 14脱甲基酶(P - 450(14DM))(青木洋、山崎彻、近藤真、菅生洋、中山直、关根洋、岛田博、有泽正,《抗生素杂志》45:160 - 170,1992;松久修、大冢彻、小田木博、泽入博、佐野哲、渡边健、中山直、伊手园洋、藤生真、岛间直、横瀬健、奥田哲,《抗生素杂志》45:151 - 159,1992)。我们研究了该化合物与真菌P - 450(14DM)的相互作用模式及其对真菌与哺乳动物P - 450酶的选择性。Ro 09 - 1470以1:1的化学计量比与酿酒酵母P - 450(14DM)结合,通过与血红素配位。与唑类化合物不同,它能与三价铁和二价铁血红素相互作用。它对白色念珠菌的P - 450(14DM)也有活性。Ro 09 - 1470优先抑制酵母P - 450(14DM),其50%抑制浓度(IC50)为0.47至约1.1微摩尔,远低于催化胆固醇生物合成的大鼠肝脏P - 450(IC50 = 341微摩尔)、对硝基苯甲醚O - 脱甲基(>1000微摩尔)、苯胺羟基化(>1000微摩尔)和氨基比林N - 脱甲基(920微摩尔)的IC50。对酵母P - 450的选择性程度高于酮康唑。